8-K current report · filed Aug 4, 2026

Amgen (AMGN) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02AMGN overview

Short answer

Amgen (AMGN) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 and six-month 2026 unaudited results, plus June 30 financial position, announced August 4, 2026.

Amgen 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 and six-month 2026 unaudited results, plus June 30 financial position, announced August 4, 2026
  • Investors must review Exhibit 99.1 for revenue, earnings, cash flow and balance-sheet figures
  • Non-GAAP results exclude acquisition-related charges, restructuring costs and selected investment and legal items
  • Free cash flow defined as GAAP operating cash flow less capital expenditures, providing a liquidity view
  • Adjusted metrics may improve comparability, but exclude recurring acquisition and restructuring economics

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $10.1B, up 10%, with product sales up 9% and six growth drivers up 26%, supporting continued portfolio momentum
  • GAAP EPS $4.37, up 65%, while non-GAAP EPS $6.29, up 4%, reflecting higher expenses and tax pressure
  • Free cash flow $3.5B versus $1.9B, strengthening liquidity despite debt rising to $57.3B from $54.6B
  • 2026 guidance maintained at revenue $38.2B-$39.4B and non-GAAP EPS $22.30-$23.50
  • Growth concentration risks: Prolia sales fell 32% and XGEVA 34% as biosimilars pressured volume and pricing; MariTide Phase 3 expansion remains a major pipeline catalyst

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Amgen 8-K filings

Get the next AMGN 8-K as it lands

Follow AMGN for push alerts, or ask the research agent what this filing means.